| Host |
Rabbit |
| Klon |
EP206 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hairy cell leukemia |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
| Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3117B |
-
|
| Host |
Rabbit |
| Klon |
EP206 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hairy cell leukemia |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
| Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
6 ml |
Ready-to-use |
CE/IVD |
API3117AA |
-
|
| Host |
Rabbit |
| Klon |
ZR404 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human ITGAE/CD103 protein fragment (aa 775-855) |
| Lokalisation |
Cell Surface and cytoplasmic |
CD103
|
Zeta Corporation |
ZR404 |
7 ml |
ready-to-use |
RUO |
Z2760RP-R |
-
|
| Host |
Mouse |
| Klon |
LF61 |
| Format |
Lyophilised |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Hairy cell leukaemia cells |
CD103 (Integrin alpha E) - PE
|
Zytomed Systems GmbH |
LF61 |
100 Tests |
Lyophilised |
RUO |
603-1521E |
-
|
| Host |
Mouse |
| Klon |
SN6 |
| Format |
Purified |
| Methode |
F, WB, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Partially purified cell membrane antigens from fresh leukaemia cells |
CD105 (Endoglin, TGF-beta1/3-Receptor)
|
Zytomed Systems GmbH |
SN6 |
200 µg |
Purified |
RUO |
603-1530 |
-
|
| Host |
Mouse |
| Klon |
ZM321 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
: Gastrointestinal stromal tumor (GIST), skin or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
| Lokalisation |
Cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
1.0 ml |
Concentrate |
CE/IVD |
Z2628ML |
-
|
| Host |
Mouse |
| Klon |
ZM321 |
| Format |
ready-to-use |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
| Verdünnung |
--- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
| Lokalisation |
cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
7 ml |
ready-to-use |
CE/IVD |
Z2628MP |
-
|
| Host |
Mouse |
| Klon |
ZM321 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
| Lokalisation |
Cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
0.5 ml |
Concentrate |
CE/IVD |
Z2628MS |
-
|
| Host |
Mouse |
| Klon |
ZM321 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
| Lokalisation |
cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
0.1 ml |
Concentrate |
CE/IVD |
Z2628MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Stromal Tumor, Skin |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
| Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
503-1440 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Stromal Tumor, Skin |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
| Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
503-1442 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Stromal Tumor, Skin |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
| Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-1444 |
-
|
| Host |
Rabbit |
| Klon |
EP10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
ER2 |
| Positivkontrolle |
Skin, gastrointestinal tumour |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
6 ml |
Ready-to-use |
CE/IVD |
ALI296G7 |
-
|
| Host |
Rabbit |
| Klon |
EP10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, gastrointestinal tumour |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
0.1 ml |
Concentrate |
CE/IVD |
CME296AK |
-
|
| Host |
Rabbit |
| Klon |
EP10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, gastrointestinal tumour |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
0.5 ml |
Concentrate |
CE/IVD |
CME296BK |
-
|
| Host |
Rabbit |
| Klon |
EP10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, gastrointestinal tumour |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
1 ml |
Concentrate |
CE/IVD |
CME296CK |
-
|
| Host |
Rabbit |
| Klon |
EP10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, gastrointestinal tumour |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
6 ml |
Ready-to-use |
CE/IVD |
PME296AA |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.17 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
optional |
| Positivkontrolle |
1:100-1:200 |
| Verdünnung |
EDTA |
| Isotyp |
IgG, Kappa |
| Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
| Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
1 ml |
Concentrate |
CE/IVD |
RMAB119 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.17 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
optional |
| Positivkontrolle |
1:100-1:200 |
| Verdünnung |
EDTA |
| Isotyp |
IgG, Kappa |
| Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
| Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB119-01 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.17 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
optional |
| Positivkontrolle |
1:100-1:200 |
| Verdünnung |
EDTA |
| Isotyp |
IgG, Kappa |
| Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
| Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB119-05 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.17 |
| Format |
ready-to-use |
| Methode |
P |
| Vorbehandlung |
optional |
| Positivkontrolle |
--- |
| Verdünnung |
EDTA |
| Isotyp |
IgG, Kappa |
| Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
| Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
6 ml |
ready-to-use |
CE/IVD |
RMPD119 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM80 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or thymus. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
| Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
1 ml |
Concentrate |
CE/IVD |
Z2390ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM80 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or thymus. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
| Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
7 ml |
Ready-to-use |
CE/IVD |
Z2390MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM80 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or thymus. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
| Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
0.5 ml |
Concentrate |
CE/IVD |
Z2390MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM80 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or thymus. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
| Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
0.1 ml |
Concentrate |
CE/IVD |
Z2390MT |
-
|
| Host |
Mouse |
| Klon |
BBK-2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 kappa |
| Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
| Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3201A |
-
|
| Host |
Mouse |
| Klon |
BBK-2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 kappa |
| Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
| Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3201B |
-
|
| Host |
Mouse |
| Klon |
BBK-2 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
| Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
6 ml |
Ready-to-use |
CE/IVD |
API3201AA |
-
|
| Host |
Rabbit |
| Klon |
ZR251 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
| Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
1 ml |
Concentrate |
CE/IVD |
Z2490RL |
-
|
| Host |
Rabbit |
| Klon |
ZR251 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
| Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
7 ml |
Concentrate |
CE/IVD |
Z2490RP |
-
|
| Host |
Rabbit |
| Klon |
ZR251 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
| Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
0.5 ml |
Concentrate |
CE/IVD |
Z2490RS |
-
|
| Host |
Rabbit |
| Klon |
ZR251 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
| Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
0.1 ml |
Concentrate |
CE/IVD |
Z2490RT |
-
|
| Host |
Mouse |
| Klon |
B-A38 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell Membrane |
CD138 (Syndecan-1)
|
Diagnostic Biosystems |
B-A38 |
1 ml |
Concentrate |
CE/IVD |
MOB588 |
-
|
| Host |
Mouse |
| Klon |
B-A38 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell Membrane |
CD138 (Syndecan-1)
|
Diagnostic Biosystems |
B-A38 |
0.1 ml |
Concentrate |
CE/IVD |
MOB588-01 |
-
|
| Host |
Mouse |
| Klon |
B-A38 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell Membrane |
CD138 (Syndecan-1)
|
Diagnostic Biosystems |
B-A38 |
0.5 ml |
Concentrate |
CE/IVD |
MOB588-05 |
-
|
| Host |
Mouse |
| Klon |
B-A38 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cell Membrane |
CD138 (Syndecan-1)
|
Diagnostic Biosystems |
B-A38 |
6 ml |
Ready-to-use |
CE/IVD |
PDM588 |
-
|
| Host |
Mouse + Rabbit |
| Klon |
B-A38 + SP4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Multiple myeloma, bone marrow, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 + IgG |
| Lokalisation |
Cell membrane (CD138), nucleus (Cyclin D1) |
CD138 + Cyclin D1
|
Biocare Medical |
B-A38 + SP4 |
6 ml |
Ready-to-use |
CE/IVD |
API3193DSAA |
-
|
| Host |
Mouse |
| Klon |
BNI3 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Human CTLA-4/human IgG heavy chain fusion protein |
CD152 (CTLA4, Cytolytic T-lymphocyte-associated Antigen 4)
|
Zytomed Systems GmbH |
BNI3 |
200 µg |
Purified |
RUO |
603-1614 |
-
|
| Host |
Mouse |
| Klon |
BNI3 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Human CTLA-4/human IgG heavy chain fusion protein |
CD152 (CTLA4, Cytolytic T-lymphocyte-associated Antigen 4) - PE
|
Zytomed Systems GmbH |
BNI3 |
100 Tests |
Purified |
RUO |
603-1619E |
-
|
| Host |
Mouse |
| Klon |
EDHu-1 |
| Format |
Purified |
| Methode |
F, P, WB, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Leucocytes harvested from pleural cavity of patients with idiopathic spontaneous pneumothorax |
CD163
|
Zytomed Systems GmbH |
EDHu-1 |
200 µg |
Purified |
RUO |
603-1623 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, placenta |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
0.1 ml |
Concentrate |
CE/IVD |
CM353AK |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, placenta |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
1 ml |
Concentrate |
CE/IVD |
CM353CK |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
1 ml |
Concentrate |
CE/IVD |
MOB460 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB460-01 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB460-05 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
6 ml |
Ready-to-use |
CE/IVD |
PDM579 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
25 ml |
Ready-to-use |
CE/IVD |
PDM579-25 |
-
|
| Host |
Mouse |
| Klon |
10D6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, placenta |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
6 ml |
Ready-to-use |
CE/IVD |
PM353AA |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM29 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liver. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human CD163 fragment (around aa 43-196) |
| Lokalisation |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
1 ml |
Concentrate |
CE/IVD |
Z2361ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM29 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liver. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human CD163 fragment (around aa 43-196) |
| Lokalisation |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
7 ml |
Ready-to-use |
CE/IVD |
Z2361MP |
-
|